Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Cycle. 2008 Mar 1;7(5):566-9. Epub 2007 Dec 29.

Metalloproteinases and cell fate: Notch just ADAMs anymore.

Author information

1
Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York 11794-8651, USA.

Abstract

Notch signaling is involved both in development as well as in multiple cancers, including pancreatic cancer. Its activity has been implicated early in pancreatic disease, shown to be essential for a pre-cancerous transdifferentiation event known as acinar-to-ductal metaplasia (ADM). Recently, we have shown that matrix metalloproteinase-7 (MMP-7) is essential for ADM by activating the Notch pathway, challenging the notion that ADAM metalloproteinases are the sole enzymes responsible for initiating Notch activity. In ADM, ADAMs do not compensate for the absence of MMP-7 activity. We propose that during development and stem cell maintenance, Notch activation is highly regulated by the binding of Notch ligand to receptor and employs the ubiquitously-expressed ADAMs, whereas in a disease state, high levels of induced MMP-7 activity can lead to aberrant ligand-independent Notch activation. Therefore, if ADM or PDA is to be blocked by inhibiting Notch, treatment with ADAM-specific inhibitors alone will be inadequate. Other approaches for Notch inhibition, including by gamma-secretase and broad-spectrum MMP inhibitors, will be discussed.

PMID:
18239463
DOI:
10.4161/cc.7.5.5531
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center